Ian Hayes

The Group's principal activity is discovering and developing novel therapeutics for the treatment of cancer. It focuses on the study of cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. The Group creates intellectual property that seeks to exploit through in-house product development and licensing.

Crescent Diagnostics Ltd. operates as a medical diagnostics company. The firm offers bone quality test, an osteoporosis screening tool that enables clinicians to identify those who are at high risk of suffering a hip fracture. The company was founded by Mark Towler and Ernest Poku in 2004 and is headquartered in London, the United Kingdom.

Radisens Diagnostics Ltd. operates as a medical diagnostics company that develops a near-patient device to instantly test for high-burden chronic disease. It specializes in the decentralization of routine blood testing from central reference laboratories into physician offices, outpatient clinics, hospital bedsides and other point-of-care settings. With a finger-prick of blood, this multi-mode diagnostic device will return laboratory-grade results within minutes during a patient’s physician visit. The firm offers patients test results for any condition, anywhere, instantly. The company was founded in 2009 by Jeremiah O'Brien and is headquartered in Ballincollig, Ireland.

OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY.